Results 31 to 36 of about 45 (36)

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

Cancer Cell
Guizhen Zhou, Xiufeng Pang
exaly  

Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma

Proceedings of the National Academy of Sciences of the United States of America, 2017
Arvin M Gouw, Livia S Eberlin, Katherine Margulis   +2 more
exaly  

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Cancer Cell, 2018
Ting Chen, Laura Gutierrez Quiceno, Shoichiro Tange   +2 more
exaly  

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

Cancer Cell
Khrystyna Myndzar, Hongbin Ji
exaly  

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

Cancer Cell
Caicun Zhou, Libo Luo, Yaxin Yu
exaly  

A first-in-class EGFR-directed KRAS G12V selective inhibitor

Cancer Cell
William D Green, Chad V Pécot
exaly